The Week

Amgen (AMGN) fell 13.7% this week to close at $377.35, while the S&P 500 slipped 0.8%, leaving AMGN roughly 12.9 percentage points behind the benchmark. The stock moved lower throughout the week: Tuesday opened at $408.90 and closed at $393.17, Wednesday edged down to $391.27, Thursday closed at $382.47, and Friday touched a weekly low of $377.22 before ending at $377.35. Trading picked up, with average daily volume of 3.86 million shares running about 63.9% above the median.

Key Events

The week’s selling was driven by sector-wide pressure rather than company-specific news. Novartis reported a Phase III failure for a cholesterol drug, triggering a broad biopharma sell-off. Amgen was not involved in that trial, but the stock fell alongside peers, at one point down more than 10% for its worst daily showing since October 2000. BMO cut its rating on Amgen the same day, adding to the decline. Midweek news was lighter: Amgen presented at the Morgan Stanley 24th Annual Global Healthcare Conference and highlighted 26% growth drivers, IMDELLTRA momentum, and MariTide potential. The company’s own Imdelltra achieved Phase III success in extensive-stage small cell lung cancer, a point cited by some analysts in keeping a buy rating on the stock.

Analyst Ratings

Across 34 covering firms, 8 rate it buy, 4 rate it overweight, 18 rate it hold, 2 rate it underweight, and 2 rate it sell. The consensus rating is hold, with a consensus target price of $388.03, about 2.8% above the latest close of $377.35. Target prices range from $225 to $457, reflecting wide disagreement. Amgen ranks second among 506 companies in the biotech industry based on analyst ratings.

The Week Ahead

On Tuesday (September 15), the New York Fed manufacturing index is due, with a prior reading of 20.6 and a forecast of 14.75. On Wednesday (September 16), a busy slate includes retail sales, retail sales ex-autos, retail control, import prices, the NAHB housing market index, and weekly EIA crude and Cushing inventory data. Whether the biopharma sector stabilises after this week’s sell-off will be a key watchpoint for AMGN.

In Short

AMGN’s sharp underperformance this week came against a backdrop of sector-wide risk-off pressure, with little evidence of a company-specific deterioration. The analyst picture is split but broadly neutral, and the consensus target price still sits marginally above spot, while the lung cancer and obesity pipeline stories remain intact. Valuation is not cheap at roughly 23.3x earnings and 17.45x book, and the latest session’s money flow showed large, medium, and small orders all tilted to net selling. The near-term question is whether next week’s macro data and sector sentiment offer a floor for the stock, and whether analyst ratings shift in either direction.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.